New directions in antibacterial research

Journal of Medicinal Chemistry

Volumn 39, Issue 20, 1996, Pages 3853-3874

  Chu, Daniel T W ^a,b,c   Plattner, Jacob J ^a,h,i,j,k   Katz, Leonard ^a,d,e,f,g  

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF NEW BRUNSWICK   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NEW YORK UNIVERSITY   (United States)

^h UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Diagnostics Division

^k Pharmaceutical Products Division

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM; CEPHALOSPORIN; MONOBACTAM; PENICILLIN DERIVATIVE;

ANTIBACTERIAL ACTIVITY; CLINICAL PRACTICE; HOSPITAL INFECTION; HOST PARASITE INTERACTION; IMMUNE RESPONSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; REVIEW; SYMBIOSIS;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACTERIA; DRUG RESISTANCE, MICROBIAL; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE;

EID: 0029796373     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960294s     Document Type: Review

References (199)

1. Rubinstein, E. Ed. Science 1994, 264, 360-393.
2. Cohen, M. L. Antimicrobial resistance: prognosis for public health. Trends Microbiol. 1994, 2, 422-425.
3. Hashimoto, H.; Inoue, M.; Hayashi, I. Resistance pattern of MRSA isolates in Japan in 1992-1993. 11th Future Trends in Chemotherapy, Geneva, Switzerland, 1994, Abstr. No. 87.
4. Mylntte, J. M.; Karuza, J.; Bentley, D. W. Methicillin-resistant Staphylococcus aureus: a questionnaire survey of 75 long-term care facilities in western New York. Infect. Control Hosp. Epidemiol. 1992, 13, 711-718.
5. Voss, A.; Doebbeling, B. The world-wide prevalence of methicillin-resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 1995, 5, 101-106.
6. Major Unmet Needs in Bacterial Infection Therapy. Infectious Disease, A Pharmacor Service, August, 1992.
7. Noble, W. C.; Virani, Z.; Cree, R. Cotransfer of vancomycin and other resistant genes from Enterococcus faecalis NCTC12201 to Staphylococcus aureus. FEMS Microbiol. Lett. 1992, 93, 195-198.
8. Veach, L. A.; Pfaller, M. A.; Barrett, M.; Koontz, F. P.; Wenzel, R. P. Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J. Clin. Microbiol. 1990, 28, 2064-2068.
9. Grayson, M. L.; Eliopoulos, G. M. Antimicrobial resistance in the intensive care unit. Semin. Respir. Infect. 1990, 5, 204-214.
10. Baquero, F.; Martinez-Beltran, J.; Loza, E. A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe. J. Antimicrob. Chemother. 1991, 28. Suppl C, 31-38.
11. Lonks, J. R.; Medeiros, A. A. High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R. I. Antimicrob. Agents Chemother. 1993, 37, 1742-1745.
12. Yoshida, R.; Kaku, M.; Kohno, S.; Ishida, K.; Mizukane, R.; Takemura, H.; Tanaka, H.; Usui, T.; Tomono, K.; Koga, H.; Hara, K. Trends in Antimicrobial resistance of Streptococcus pneumoniae in Japan. Antimicrob. Agents Chemother. 1995, 39, 1196-1198.
13. Bloom, B. R.; Murray, C. J. L. Tuberculosis: commentary on a reemergent killer. Science 1992, 257, 1055-1064.
14. Chopra, I. Mode of action of the tetracyclines and the nature of bacterial resistance to them. In The Tetracyclines, Handbook of Experimental Pharmacology; Hlavka, J. J., Boothe, J. H., Eds.; Springer-Verlag: Berlin, 1985; Vol. 78, pp 317-392.
15. Chopra, I. Molecular mechanisms involved in the transport of antibiotics into bacteria. Parasitology 1988, 96, S25-S44.
16. Eliopoulos, G. M.; Wennerstein, C. B.; Cole, G.; Moellering, R. C. In vitro activities of two glycylcyclines against gram-positive bacteria. Antimicrob. Agents Chemother. 1994, 38, 534-541.
17. Speer, B. S.; Shoemaker, N. B.; Salyers, A. A. Bacterial resistance to tetracycline: mechanism, transfer, and clinical significance. Clin. Microbiol. Rev. 1992, 5, 387-399.
18. McMurry, L.; Petrucci, R. E., Jr.; Levy, S. B. Active efflux of tetracycline encoded by four genetically different tetracycline resistant determinants in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 3974-3977.
19. Levy, S. B.; McMurry, L. Detection of an inductive membrane protein associated with R-factor mediated tetracycline resistance. Biochem. Biophys. Res. Commun. 1974, 56, 1080-1088.
20. Burdett, V. Streptococcal tetracycline resistance mediated at the level of protein synthesis. J. Bacteriol. 1986, 165, 564-569.
21. Sanchez-Pescador, R.; Brown, J. T.; Roberts, M.; Ureda, M. S. Homology of TetM with translational elongation factors: implications for potential modes of tetM conferred tetracycline resistance. Nucleic Acids Res. 1988, 16, 1218.
22. Nelson, M. L.; Park, B. H.; Andrew, J. S.; Georgian, V. A.; Thomas, R. C.; Levy, S. B. Inhibition of the tetracycline efflux antiport protein by 13-thio-substituted-5-hydroxy-6-deoxy-tetracyclines. J. Med. Chem. 1993, 36, 370-377.
23. Nelson, M. L.; Park, B. H.; Levy, S. B. Molecular requirement for the inhibition of the tetracycline antiport protein and the effect of potent inhibitors on the growth of tetracycline-resistant bacteria. J. Med. Chem. 1994, 37, 1355-1361.
24. Sum, P. E.; Lee, V. J.; Testa, R. T.; Hlavka, J. J.; Ellestad, G. A.; Bloom, J. D.; Gluzman, Y.; Tally, F. P. Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines. J. Med. Chem. 1994, 37, 184-188.
25. Barden, T. C.; Buckwalter, B. L.; Testa, R. T.; Petersen, P. J.; Lee, V. J. "Glycylcyclines". 3. 9-Aminodoxycyclinecarboxamides. J. Med. Chem. 1994, 37, 3205-3211.
26. Wise, R.; Andrews, J. M. In vitro activities of two glycylcyclines. Antimicrob. Agents Chemother. 1994, 38, 1096-1102.
27. Goldstein, F. W.; Kitzis, M. D.; Acar, J. F. N,N-Dimethylglycylamido derivatives of minocycline and 6-demethyl-6-desoxytetracycline. Two new glycylcyclines highly effective against tetracycline-resistant gram-positive cocci. Antimicrob. Agents Chemother. 1994, 38, 2218-2220.
28. Ishii, Y.; Ohne, A.; Miyazaki, S.; Tatea, K.; Matsumoto, T.; Yamaguchi, K. A study of antimicrobial activity of CL331,928 (DMG-DMDOT) and MINO on Staphylococcus aureus. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994, Abstr. No. F88.
29. Reynold, P. E. Inhibitors of bacterial cell wall synthesis. In The Scientific Basis of Antimicrobial Chemotherapy, 38th Symposium of the Society for General Microbiology; Greenwood, D., O'Grady, F., Eds.; Cambridge University Press: Cambridge, 1985; pp 13-40.
30. Arthur, M.; Courvalin, P. Genetics and mechanism of glycopeptide resistance enterococci. Antimicrob. Agents Chemother. 1993, 57, 1563-1571.
31. Leclercq, R.; Derlot, E.; Weber, M.; Duval, J.; Courvalin, P. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 1989, 33, 10-15.
32. Kaplan, A. H.; Gilligan, P. H.; Facklam, R. R. Recovery of resistant enterococci during vancomycin prophylaxis. J. Clin. Microbiol. 1988, 26, 1216-1218.
33. Courvalin, P. Resistance of enterococci to glycopeptides. Antimicrob. Agents Chemother. 1990, 33, 2291-2296.
34. Goldstein, F. W.; Zhou, X. Y.; Acar, J. F. Antibacterial activity of MDL 62873 against teicoplanin-resistant coagulase negative staphylococci. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1990, Abstr. No. 803.
35. Goldstein, B. P.; Candiani, G. P.; Arain, T. M.; Romano, G.; Cicilliato, I.; Berti, M.; Abbondi, M.; Scotti, R.; Mainini, M.; Ripamonti, F.; Resconi, A.; Denaro, M. Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic. Antimicrob. Agents Chemother. 1995, 39, 1580-1588.
36. Borgonovi, M.; Cavenaghi, L. A.; Borghi, A.; Galimberti, M.; Kaltofen, P.; Merati, R.; Coutant, J. E. Pharmacokinetics of MDL 63,246, a new semisynthetic glycopeptide antibiotic, in the rat. Antimicrob. Agents Chemother. 1995, 39, 2176-2182.
37. Synder, N. J.; Mullen, D. L.; Butler, T. F.; Nicas, T. I.; Zweifel, M. J.; Wilkie, S. C.; Rodriguez, M. J.; Thompson, R. C.; Cooper, R. D. G. Parallel modification of natural glycopeptides: synthesis and antibacterial activity. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F243.
38. Nicas, T. I.; Flokowitsch, J. E.; Preston, D. A.; Mullen, D. L.; Grissom-Arnold, J.; Snyder, N. J.; Zweifel, M. J.; Wilkie, S. C.; Rodriguez, M. J.; Thompson, R. C.; Cooper, R. D. G. Semisynthetic glycopeptides active against vancomycin-resistant enterococci: Activity against staphylococci and streptococci in vitro and in vivo. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F248.
39. Nicas, T. I.; Mullen, D. L.; Grissom-Arnold, J.; Snyder, N. J.; Zweifel, M. J.; Wilkie, S. C.; Rodriguez, M. J.; Thompson, R. C.; Cooper, R. D. G. Semi-synthetic glycopeptides active against vancomycin-resistant enterococci: In vitro activity against enterococci. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F249.
40. Boylan, C. J.; Nicas, T. I.; Preston, D. A.; Zeckner, D. L.; Boyll, B. J.; Raab, P. A.; Mullen, D. L.; Snyder, N. J.; Zomes, L. L.; Stratford, R. E.; Zweifel, M. J.; Wilkie, S. C.; Rodriguez, M. J.; Thompson, R. C.; Cooper, R. D. G. Efficacy of semisynthetic glycopeptides active against vancomycin-resistant enterococci in a mouse infection model. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F255.
41. Lin, Y.; Stratford, R. E.; Zornes, L. L.; Confer, W. L.; Vasudevan, V.; Jones, T. W.; Nicas, T. I.; Preston, D. A.; Boylan, C. J.; Zeckner, D. L.; Boyll, B. J.; Raab, P. A.; Snyder, N. J.; Zweifel, M. J.; Wilkie, S. C.; Rodriguez, M. J.; Thompson, R. C.; Cooper, R. D. G. Non-clinical pharmacokinetics of LY333328, a semisynthetic glycopeptide active against vancomycin-resistant enterococci. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F254.
42. LeTourneau, D. L.; Hobbs, J. N., Jr.; Allen, N. E. Molecular interactions of LY 264826 and its p-chlorobenzyl derivative, LY191145, with dipeptidyl and didepsipeptidyl ligands. 35th Interscience Conference on Antimicrobial agents and Chemotherapy, 1995, Abstr. No. F251.
43. Ghuysen, J. M. Serine β-lactamases and penicillin-binding proteins. Annu. Rev. Microbiol. 1991, 154, 37-67.
44. Silver, L. L.; Bostian, K. A. Discovery and development of new antibiotics: the problem of antibiotic resistance. Antimicrob. Agents Chemother. 1993, 37, 377-383.
45. Brown, A. G.; Butterworth, D.; Cole, M.; Hanscomb, G.; Hood, J. D.; Reading, C.; Robinson, G. N. Naturally-occuring beta-lactamase inhibitors with antibacterial activity. J. Antibiot. 1976, 29, 668-669.
46. Fujii, R.; Nishimura, T. Pharmacokinetics and clinical studies of tazobactam/piperacillin in the pediatrics. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F156.
47. Angehm, P.; Gutknecht, E.-M. Bridged β-lactam Ro 48-1256. Antibacterial activity in combination with cephalosporins and imipenem. 35th Interscience Conference on Antimicrobial agents and Chemotherapy, 1995, Abstr. No. F148.
48. Nikaido, H. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob. Agents Chemother. 1989, 33, 1831-1836.
49. Quinn, J. P.; Dudek, E. J.; diVincenzo, C. A.; Lucks, D. A.; Lerner, S. A. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J. Infect. Dis. 1986, 54, 289-294.
50. Mochizuki, H.; Yamada, H.; Oikawa, Y.; Ishiguro, J.; Kosuzume, H.; Aizawa, N.; Mochida, E. Mechanism of action of M14659: uptake of M14659 through the bacterial iron-transport system. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988, Abstr. No. 428.
51. Zama, Y.; Naito, T.; Hirose, M.; Yokoyama, M.; Saito, T.; Ishiyama, N.; Sanai, S.; Saga, K. New parenteral cephalosporins with anti-pseudomonal activity: structure-activity relationships leading to KP-736. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989, Abstr. No. 481.
52. Ikeda, D.; Huang, S.-P.; Koyama, Y.; HamadA, M.; Kondo, S.; Takeuchi, T. New parenteral 3-isoxazolidinylcephalosporins, SPD-391 and SPD-411. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1990, Abstr. No. 458.
53. Akaniro, J. C.; Stutman, H. R.; Vidaurre, C. E.; Marks, M. I.; Arrieta, A. C. In vitro activity of BO-1341, a novel cephalosporin, against isolates from bacteremic and cystic fibrosis patients. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1990, Abstr. No. 466.
54. Aszodi, J.; Humbert, D.; Bonnefoy, A.; Collette, P.; Mauvais, P.; Chanlot, J. F. RU 59863, a novel catechol-substituted vinylogous cephalosporin: In vitro antibacterial activity. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994, Abstr. No. F99.
55. Kwak, J. H.; Kim, S. I.; Oh, J. I.; Song, H. K.; Kim, M. Y.; Seo, M. K.; Jeong, Y. N.; Lee, Y. H.; Kim, Y. Z.; Kim, I. C. In vitro and in vivo activities of LK10517, a novel catechol-substituted cephalosporin. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994, Abstr. No. F93.
56. Barbachyn, M. R.; Tuominen, T. C. Structure-activity relationships of a series of monocarbams leading to U-78,608. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988, Abstr. No. 231.
57. Ermann, P.; Sundeen, J. E.; Drossard, J.-M.; Jendrzejewski, S.; Lis, K.; Strub, H. Structure-activity relationships in a new series of mono-bactams carrying bicyclic catechol surrogates. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1990, Abstr. No. 825.
58. Kolek, B.; Fung-Tomc, J.; Minassian, B.; Flamm, R.; Kessler, R. E.; Bonner, D. P. In vitro activity of novel catechol-containing monobctam, BMS-180680. 34th Interscience Conference on Antimicrobial agents and Chemotherapy, 1994, Abstr. No. F143.
59. Matsumoto, M.; Horimoto, H.; Shizuta, T.; Ishikawa, H.; Kikuchi, M. OPC-20000s, novel parenteral cephalosporins- structure and activity relations. 33th Interscience Conference on Antimicrobial agents and Chemotherapy, 1993, Abstr. No. 887.
60. Curtis, N. A.; Eisenstadt, R. L.; East, S. J.; Comford, R. A.; Walker, L. A.; White, A. W. Iron-regulated outer membrane proteins of Escherichia coli K-12 and mechanism of action of catechol-substituted cephalosporins. Antimicrob. Agents Chemother. 1988, 32, 1879-1866.
61. Nikaido, H.; Rosenberg, E. Y. Cir and Fiu proteins in the outer membrane of Escherichia coli catalyze transport of monomeric catechols; study with β-lactam antibiotics containing catechol and analogous groups. J. Bacteriol. 1990, 772, 1361-1367.
62. Silley, P.; Griffiths, J. W.; Monsy, D. Mode of action of GR69153, a novel catechol-substituted cephalosporin, and its interaction with the tonB-dependent iron transport system. Antimicrob. Agents Chemother. 1990, 34, 1806-1808.
63. Berger-Bachi, B. Expression of resistance to methicillin. Trends Microbiol. 1994, 2, 387-393.
64. Hammond, G. G.; Overbye, K. M.; Silver, L. L. Binding of L-695,256, a prototypical 2-aryl carbapenem antibiotic, to penicillin binding proteins of methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus hirae. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994, Abstr. No. F62.
65. Meurer, L.; Guthikonda, R.; Huber, J.; DiNinno, F. The synthesis and antibacterial activity of 2-carbolinylcarbapenems: potent anti-MRSA/MRCNS agents. Bioorg. Med. Chem. Lett. 1995, 5, 767-772.
66. Og, C.-H.; Ham, Y.-W.; Hong, S.-Y.; Cho, J.-H. Synthesis and antibacterial activity of new 1-β methyl carbapenem having a thiazolo[3,2-a] benzimidazole moiety. Arch. Pharm (Weinheim, Ger.) 1995, 328, 289-291.
67. Sumita, Y.; Nouda, H.; Kanazawa, K.; Fukasawa, M. Antimicrobial activity of SM-17466, a novel carbapenem antibiotic with potent activity against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 1995, 39, 910-916,
68. New carbapenem derivatives are antimicrobial agents- particularly useful against multiple drug resistant strains of MRSA and P. aeruginosa. JP 7133277-A, 1995, Japan.
69. Wise, R.; Andrews, J. M.; Edwards, L. J. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob. Agents Chemother. 1983, 23, 559-564.
70. Gellert, M.; Mizuuchi, K.; O'Dea, M. H.; Itoh, T.; Tomizawa, J,-I. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc. Nat. Acad. Sci. U.S.A. 1977, 74, 4772-4776.
71. Ferrero, L.; Cameron, L. B.; Manse, B.; Lagneaux, D.; Crouzet, J.; Famechon, A.; Blanche, F. Cloning and primary structure of Straphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 1994, 13, 641-653.
72. Ferrero, L.; Cameron, B.; Crouzet, J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphlococcus aureus. Antimicrob. Agents Chemother. 1995, 39, 1554-1558.
73. Heisig, P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 1996, 40, 879-885.
74. Thornsberry, C.; Brown, S. D.; Bouchillon, S. K.; Marier, J.; Rich, T.; Yee, Y. C. United States Surveillance of Clinical Bacterial Isolates to Ciprofloxacin; Institute of Microbiology Research: Franklin, TN, 1993.
75. Sreedharan, S.; Oram, M.; Jensen, B.; Peterson, L. R.; Fisher, L. M. DNA gyrase gyrA mutations in ciprofloxacin-resistance strain of Staphylococcus aureus: close similarity with quinolone resistance mutation in Escherichia coli. J. Bacteriol. 1990, 172, 7260-7262.
76. Kaatz, G. W.; Seo, S. M.; Ruble, C. A. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 1993, 37, 1086-1094.
77. Yoshida, H.; Bogaki, M.; Nakamura, M.; Nakamura, S. Quinolone resistance-determining region in the DNA gygrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 1990, 34, 1271-1272.
78. Barrett, M. S.; Jones, R. N.; Erwin, M. E.; Johnson, D. M.; Briggs, B. M. Antimicrobial activity evaluations of two new quinolones, PD 127391 (CI-960 and AM-1091) and PD 131628. Diagn. Microbiol. Infect. Dis. 1991, 14, 389-401.
79. Gootz, T. D.; Brighty, K. E.; Anderson, M. E.; Haskell, S. L.; Sutcliffe, J. A.; Castaldi, M. J.; Miller, S. A. In vitro activity and synthesis of CP-99219, a novel 7-(3-azabicyclo[3.1.0] hexyl) naphthyridone. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1992, Abstr. No. 751.
80. Sato, K.; Hoshino, K.; Tanaka, M.; Hayakawa, I.; Osada, Y. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob. Agents Chemother. 1992, 36, 1491-1498.
81. Fuchs, P. C.; Barry, A. L.; Pfaller, M. A.; Allen, S. D.; Gerlach, E. H. Multicenter evaluation on the in vitro and in vivo activities of three new quinolones, sparfloxacin, CI-960 and PD 131628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob. Agents Chemother. 1991, 35, 764-766.
82. Forstall, G. J.; Knapp, C. C.; Washington, J. A. Activity of new quinolones against ciprofloxacin-resistant staphylococci. Antimicrob. Agents Chemother. 1991, 35, 1679-1681.
83. Neu, H. C.; Chin, N. X. In vitro activity of CP-99219, &-(3-azabicydo[3.1.0]hexylnaphthyridone. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1992, Abstr. No. 754.
84. Eliopoulos, G. M.; Klimm, K.; Eliopoulos, C. T.; Ferrara, M. J.; Moellering, R. C., Jr. In vitro activity of CP-99219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 1993, 37, 366-370.
85. Girard, A. E.; Girard, D.; Gootz, T. D.; Faiella, J. A.; Cimochowski, C. R. In vitro efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob. Agents Chemother. 1995, 39, 2210-2216.
86. Korten, V.; Tomayko, J. F.; Murray, B. Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against grampositive cocci. Antimicrob. Agents Chemother. 1994, 38, 611-615.
87. Kitamura, A.; Hoshino, K.; Kimura, Y.; Hayakawa, I.; Sato, K. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1995, 39, 1467-1471.
88. Yokoyama, Y.; Morimoto, M.; Iwao, E.; Yamamoto, K.; Honjo, K.; Hirayama, F.; Ikeda, Y. Y-688, a new fluoroquinolone with high activity against quinolone resistant gram-positive bacteria. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F191.
89. Okezaki, E.; Watanabe, Y.; Hirose, T.; Yoshida, T.; Aoki, Y.; Kato, H. Antibacterial activity of HRS-903, a new novel quinolone. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F191.
90. Chu, D. T. W.; Li, Q.; Claiborne, A.; Raye-Passarelli, C.; Copper, C.; Fung, A.; Lee, C.; Tanaka, K.; Shen, L. L.; Donner, P.; Armiger, Y.; Plattner, J. J. Synthesis and antibacterial activity of A-86719.1 and related 2-pyridones: a novel series of potent DNA gyrase inhibitors. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994, Abstr. No. F41.
91. Eliopoulos, G. M.; Wennerstein, C. B.; Cole, G.; Chu, D.; Pizzuti, D.; Moellering, R. C., Jr. In vitro activity of A-86719.1, a novel 2-pyridone antimicrobial agent. Antimicrob. Agents Chemother. 1995, 39, 850-853.
92. Flamm, R. K.; Vojtko, C.; Chu, D. T. W.; Li, Q.; Beyer, J.; Hensey, D.; Ramer, N.; Clement, J. J.; Tanaka, K. In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor. Antimicrob. Agents Chemother. 1995, 39, 964-970.
93. Alder, J.; Clement, J.; Meulbroek, J.; Shipkowitz, N.; Mitten, M.; Jarvis, K.; Oleksijew, A.; Hutch, T., Sr.; Paige, L.; Flamm, R.; Chu, D.; Tanaka, K. Efficies of ABT-719 and related 2-pyridones, members of a new class of antibacterial agents, against experimental bacterial infections. Antimicrob. Agents Chemother. 1995, 39, 971-975.
94. Li, Q.; Clairborne, A.; Chu, D. T. W.; Lee, C. M.; Raye, K. A.; Berst, K.; Ma, Z.; Wang, W.; Shen, L. S.; Flamm, R.; Nilius, A.; Alder, J.; Marsh, K.; Shortridge, V. D.; Tanaka, S. K.; Seif, L.; Cooper, C.; Fung, A.; Tufano, M.; Melcher, L. M.; Henry, R.; Klein, L.; Plattner, J. J. Synthesis and in vitro antibacterial activity of novel DNA gyrase inhibitors. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F8.
95. Fung, A. K. L.; Chu, D. T.; Armiger, Y. L.; Li, Q.; Tanaka, S. K.; Flamm, R. K.; Shen, L.; Baranowski, J.; Marsh, K.; Crowell, D.; Plattner, J. J. Synthesis and structure-activity relationship of 8-[3-(1-aminoalkyl) pyrrolidinyl]-and 8-[3-(1-aminocydoalkyl) pyrrolidinyl]-2-pyridopyridone antibacterials. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F9.
96. Kamiyama, T.; Shimma, N.; Ohtsuka, T.; Nakayama, N.; Itezono, Y.; Nakada, N.; Watanabe, J.; Yokose, K. Cyclothialidine, a novel DNA gyrase inhibitor II. Isolation, characterization and structure elucidation. J. Antibiot. 1994, 47, 37-45.
97. Nakada, N.; Shimada, H.; Hirata, T.; Aoki, Y.; Kamiyama, T.; Watanabe, J.; Arisawa, M. Biological characterization of cyclothialidine, a new DNA gyrase inhibitor. Antimicrob. Agents Chemother. 1993, 37, 2656-2661.
98. Morimoto, S.; Takahashi, Y.; Watanabe, Y.; Omura, S. Chemical modification of erythromycin I. Synthesis and antibacterial activity of 6-O-methylerythromycin A. J. Antibiot. 1984, 37, 343-345.
99. Bright, G.; Nagel, A.; Bordner, J.; Desai, K.; Dibrino, J.; Nowakowska, J.; Vincent, L.; Watrous, R.; Sciavolino, F.; English, A.; Retsema, J.; Anderson, M.; Brennan, L.; Borovoy, R.; Cimchowsji, C.; Faiella, J.; Girard, A.; Girard, D.; Herbert, C.; Manousos, M.; Mason, R. Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a-homoerythromycin A derivatives: a new class of macrolide antibiotics, the azalides. J. Antibiot. 1988, 41, 1029-1047.
100. Brisson-Noel, A.; Trieu-Cuot, P.; Courvalin, P. Mechanism of action of spiramycin and other macrolides. J. Antimicrob. Chemother. 1988, 22 (suppl. B), 13-23.
101. Gardee, Y.; Kirby, R. The incidence of inducible macrolide-lincosamide-streptogramin B resistance in methicillin- resistant staphylococci in clinical isolates from the Eastern Cape area of South Africa. Lett. Appl. Microbiol. 1993, 17, 264-268.
102. Fernandes, P. Baker, W.; Freiberg, L.; Hardy, D.; McDonald, E. New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. Antimicrob. Agents Chemother. 1989, 33, 78-81.
103. Agouridas, C.; Benedetti, Y.; Denis, A.; Le Martret, O.; Chantot, J. F. Ketolides: a new distrnct class of macrolide antibacterials, synthesis and structural characteristics of RU 004. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F157.
104. Agouridas, C.; Bonnefoy, A.; Chantot, J. F. In vitro antibacterial activity of RU 004, a novel ketolide highly active against respiratory pathogens. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F158.
105. Ednie, L.; Jacobs, M. R.; Appelbaum, P. C. Activity of the Ketolide RU 004 compared to 15 other agents against 112 erythromycin susceptible and resistant pneumococci. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F159.
106. Dabernat, H.; Seguy, M.; Delmas, C. In vitro activity of RU 004 against Haemophilus influenzae and Moraxella catarrhalis. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F161.
107. Rajagopalan-Levasseur, P.; Vallee, E.; Agouridas, C.; Chantot, J. F.; Pocidalo, J. J. RU 004: Activity against erythromycin-resistant pneumococci and Haemophilus influenzas in murine pneumonia models. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F173.
108. Agouridas, C.; Collette, P.; Mauvais, P.; Chantot, J. F. RU 004: Preliminary studies on the mechanism of action. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F170.
109. Asaka, T.; Kashimura, M.; Misawa, Y.; Ono, T.; Suzuki, K.; Yoshida, H.; Yoshida, T.; Akashi, T.; Yokoo, C.; Nagate, T.; Morimoto, S. A new macrolide antibiotic, TE-802; synthesis and biological properties. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F177.
110. Asaka, T.; Kashimura, M.; Misawa, Y.; Ono, T.; Suzuki, K.; Yoshida, H.; Yoshida, T.; Akashi, T.; Nagate, T.; Morimoto, S. A new macrolide antibiotic, TE-810; synthesis and biological properties. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F176.
111. Eustice, D. C.; Feldman, P. A.; Zajac, I.; Slee, A. M. Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis. Antimicrob. Agents Chemother. 1988, 32, 1218-1222.
112. Slee, A. M.; Wuonola, M. A.; Mcripley, R. J.; Zajac, I.; Zawada, M. J.; Bartholomew, P. T.; Gregory, W. A.; Forbes, M. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP721. Antimicrob. Agents Chemother. 1987, 31, 1791-1797.
113. Brickner, S. J.; Hutchinson, D. K.; Barbachyn, M. R.; Garmon, S. A.; Grega, K. C.; Hendges, S. K.; Manninen, P. R.; Toops, D. S.; Ulanowicz, D. A.; Kilburn, J. O.; Glickman, S.; Zurenko, G. E.; Ford, C. W. Synthesis of U-100592 and U-100766, two new oxazolidinone antibacterial agents in clinical trials for treatment of multiple-resistant gram-positive infections. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F208.
114. Zurenko, G. E.; Yagi, B. H.; Schaadt, R. D.; Allison, J. W.; Hutchinson, D. K.; Barbachyn, M. R.; Brickner, S. L. In vitro antibacterial activity of U-100592 and U-100766, novel oxazolidinone antibiotics. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F216.
115. Ford, C. W.; Hamel, J. C.; Moerman, J. K.; Stapert, D.; Wilson, D. M.; Yancey, R. J.; Barbachyn, M. R.; Hutchinson, D. K.; Bricker, S. J. In vivo efficacy evaluations of U-100592 and U-100766, new oxazolidinone antibiotics. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. F221.
116. Moazed, D.; Noller, H. F. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 1987, 327, 389-394.
117. Yamaski, T.; Narita, Y.; Hoshi, H.; Aburaki, S.; Kamei, H.; Naito, T.; Kawaguchi, H. Synthesis and biological activity of 1-N-[4-(substituted) amidino and guanidino-2-hydroxybutyl] kanamycins A and B. J. Antibiot. 1991, 44, 646-658.
118. Kettenring, J. K.; Ciabatti, R.; Winters, G.; Tamborini, G.; Cavalleri, B. Ramoplanin (A-16686), a new glycolipodesipeptide antibiotic IV. Complete sequence determination by homonuclear 2D NMR spectroscopy. J. Antibiot. 1989, 42, 268-275.
119. Jones, R. N.; Barry, A. L. In vitro evaluation of ramoplanin (A 16686 or MDL 62198), a new depsipeptide complex for potential topical use. Diagn. Microbiol. Infect. Dis. 1989, 12, 279-282.
120. Sommer, E. A.; Reynolds, P. E. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob. Agents Chemother. 1990, 34, 413-419.
121. Collins, L. A.; Eliopoulos, G. M.; Wennerstein, C. B.; Ferraro, M. J.; Moellering, R. C., Jr. In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms. Antimicrob. Agents Chemother. 1993, 37, 1364-1366.
122. Scotti, R.; Dulworth, J. K.; Kenny, M. T.; Goldstein, B. P. Effect of protein on ramoplanin broth microdilution minimum inhibitory concentration. Diagn. Microbiol. Infect. Dis. 1993, 17, 209-211.
123. Berti, M.; Romano, G.; Goldstein, B. P. Coating with ramoplanin reduces S. aureus colonization of catheter segments implanted subcutaneoudly in mice. 35th Interscience Conference on Antimicrobial agents and Chemotherapy, 1995, Abstr. No. F258.
124. Romeo, B.; Kaschube, M.; Cavenaghi, L.; Borgonovi, M.; Jaulmac, B.; Monteil, H.; Gardner, S.; Seppala, A. Repeated doses of ramoplanin orally administered to healthy male volunteers: tolerability, lack of absorption and effect on stool microflora. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1993, Abstr. No. 448.
125. Selva, E.; Beretta, G.; Montanini, N.; Saddler, G. S.; Gastaldo, L.; Ferrari, P.; Lorenzetti, R.; Landini, P.; Ripamonti, F.; Goldstein, B. P.; Berti, M.; Montanaro, L.; Denaro, M. Antibiotic GE-2270A: a novel inhibitor of bacterial protein synthesis. J. Antibiot. 1991, 44, 693-701.
126. Goldstein, B. P.; Berti, M.; Ripamonti, F.; Candiani, G. P.; Romanó, G.; Bellini, S.; Denaro, M. Antimicrobial activity of GE-2270A, a new peptide antibiotic which inhibitis protein synthesis elongation factor EF-Tu. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1990, Abstr. No. 800.
127. Selva, E.; Ferrari, P.; Colombo, L.; Tavecchia, P.; Restelli, G.; Ripamonti, F.; Denaro, M. Natural antibiotics related to GE-2270A: Isolation, structure elucidation, and biological characterization. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, 1991, Abstr. No. 415.
128. Tavecchia, P.; Landini, P.; Lociuro, S.; Goldstein, B. P.; Ciabatti, R.; Denaro, M. Antimicrobial activity of derivatives of antibiotic MDL 62,679 (GE 2270 A). 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, 1991, Abstr. No. 416.
129. Barriere, J. C.; Bouanchaud, D. H.; Harris, N. V.; Paris, J. M.; Rolin, O.; Smith, C. The design, synthesis and properties of RP 59500 and related semi-synthetic streptogramin antibiotics. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1990, Abstr. No. 768.
130. Hoban, D. J.; Weshnoweski, B.; Palatnick, L. In vitro activity RP59500, a new semi-synthetic streptogramin antibiotic against Staphylococcus species. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1990, Abstr. No. 770.
131. Lorian, V.; Fernandes, F, Synergistic activity of injectable streptogramin RP 59500 (quinuoristin/dalfopristin) vancomycin combination. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. E126.
132. Jorgensen, J. H.; McElmeel, M. L.; Liaci, J. A. Activity of RP 59500 and its components, quinupristin/dalfopristin, against Haemophilus influenzae. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, Abstr. No. E125.
133. Selsted, M. E.; Brown, D. M.; DeLange, R. J.; Harwig, S. S. L.; Lehrer, R. I. Primary structures of six antimicrobial peptides of rabbit peritoneal neutrophils. J. Biol. Chem. 1985, 260, 4579-4582.
134. Selsted, M. E.; Harwig, S. S. L.; Ganz, T.; Schilling, J. W.; Lehrer, R. I. Primary structures of three human neutrophil defensins. J. Clin. Invest. 1985, 76, 1436-1439.
135. Ganz, T. Extracellar release of antimicrobial defensins by human polymorphonuclear leukocytes. Infect. Immunol. 1987, 55, 568-571.
136. Ganz, T.; Selsted, M. E.; Harwig, S. S. L.; Szklarek, D.; Daher, K.; Lehrer, R. I. Defensins, natural peptide antibiotics of human neutrophils. J. Clin. Invest. 1985, 76, 1427-1435.
137. Segal, G. P.; Lehrer, R. I.; Selsted, M. E. In vitro effect of phagocyte cationic peptides on Coccidioides immitis. J. Infect. Dis. 1985, 151, 890-894.
138. Zasloff, M.; Martin, B.; Chen, H.-C. Antimicrobial activity of synthetic magainin peptides and several analogues. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 910-913.
139. Loebenberg, D.; Cacciapuoti, A.; Naples, L.; Moss, E. L., Jr.; Menzel, F., Jr.; Hare, R. S.; Miller, G. H. Biological activity of SCH 27899 (EVE), an everninomicin antibiotic. 33srd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1993, Abstr. No. 456.
140. Shlaes, D. M.; Shlaes, J. H.; Etter, L.; Hare, R. S.; Miller, G. H. SCH 27899 (EVE), an everninomicin active against multipy-resistant (R) enterococci and staphylococci. 33srd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1993, Abstr. No. 460.
141. Lai, C.; Weisblum, B. Altered methylation of ribosomal RNA in an erythromycin-resistant strain of Staphylococcus aureus. Proc. Nat. Acad. Sci. U.S.A. 1971, 68, 856-860.
142. Skinner, R.; Cundliffe, E.; Schmidt, F. Site of action of a ribosomal RNA methylase responsible for resistance to erythromycin and other antibiotics. J. Biol. Chem. 1983, 258, 12702-12706.
143. Brimacombe, R.; Greuer, B.; Mitchell, P.; Osswald, M.; Rinke-Appel, J.;
144. Moazed, D.; Noller, H. F. Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA. Biochemie 1987, 69, 879-884.
145. Su, S.; Dubnau, D. Binding of Bacillus subtilis ErmC′ methyl-transferase to 23S rRNA Biochemistry 1990, 29, 6033-6042.
146. Douthwaite, S.; Aagaard, C. Erythromycin binding is reduced in ribosomes with conformation alterations in the 23S rRNA peptidyl transferase loop. J. Mol. Biol. 1993, 232, 725-731.
147. Vazquez, D.; Munro, R. E. Effects of some inhibitors of protein synthesis on the binding of aminoacyl t-RNA to ribosomal subunits. Biochim. Biophys. Acta 1967, 142, 155-173.
148. Leclercq, R.; Courvalin, P. Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria. Antimicrob. Agents Chemother. 1991, 35, 1273-1276.
149. Uchiyama, H.; Weisblum, B. N-Methyl transferase of Streptomyces erythraeus that confers resistance to the macrolide-lincosamide-streptogramin B antibiotics: amino acid sequence and its homology to cognate R-factor enzymes from pathogenic bacilli and cocci. Gene 1985, 38, 103-110.
150. Kamimiya, S.; Weisblum, B. Translational attenuation control of ermSF, an inducible resistance determinant encoding rRNA N-methyltransferase from Streptomyces fradiae. J. Bacteriol. 1987, 170, 1800-1811.
151. Dubnau, D. Translational attenuation: the regulation of bacterial resistance to the macrolide-lincosamide-streptogramin B antibiotics. Crit. Rev. Biochem. 1986, 16, 103-131.
152. Weisblum, B. Insights into erythromycin action from studies of its activity as inducer of resistance. Antimicrob. Agents Chemother. 1995, 39, 797-805.
153. Ross, J.; Eady, E.; Cove, J.; Cunliff, W.; Baumberg, S.; Wooton, J. Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-binding transport super-gene family. Mol. Microl. 1990, 4, 1207-1214.
154. Goodman, R.; Capobianco, J. Role of an energy dependent efflux pump in plasmid pNE24-mediated resistance to 14-,15-membered macrolides in Staphylococcus epidermidis. Antimicrob. Agents Chemother. 1990, 34, 1973-1980.
155. Milton, I. D.; Hewitt, C. L.; Harwood, C. R. Cloning and sequencing of a plasmid-mediated erythromycin resistance determinant from Staphylococcus xylosus. FEMS Microbiol. Lett. 1992, 97, 141-147.
156. Wondrack, L.; Sutcliffe, J. Streptococcus strains with a M phenotype efflux erythromycin. 95th General Meeting Amer. Soc. Microbiol., 1995, Abstr. No. A-85.
157. Ma, D.; Cook, D. N.; Alberti, M.; Pon, N. G.; Nikaido, H.; Hearst, J. E. Molecular cloning and characterization of acrA and acrE genes of Escherichia coli. J. Bacteriol. 1993, 175, 6299-6313.
158. Poole, K.; Heinrichs, D. E.; Neshat, S. Cloning and sequence analysis of an EnvCD homologue in Pseudomonas aeruginosa: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. Mol. Microbiol. 1993, 10, 529-544.
159. Barthelemy, P.; Autissier, D.; Gerbaud, G.; Courvalin, P. Enzymic hydrolysis of erythromycin by a strain of Escherichia coli. A new mechanism of resistance. J. Antibiot. 1985, 37, 1692-1696.
160. Andremont, A.; Gebaud, G.; Courvalin, P. Plasmid-mediated high level resistance to erythromycin in Escherichia coli. Antimicrob. Agents Chemother. 1986, 29, 515-518.
161. Ounissi, H.; Courvalin, P. Nucleotide sequence of the gene ereA encoding the erythromycin esterase in Escherichia coli. Gene 1985, 35, 271-278.
162. Arthur, M.; Autissier, D.; Courvalin, P. Analysis of the nucleotide sequence of the ereB gene encoding the erythromycin esterase type II. Nucleic Acids Res. 1986, 14, 4987-4999.
163. Wondrack, L.; Massa, M.; Yang, B.; Sutcliffe, J. A clinical strain of Staphylococcus aureus produces a macrolide-specific esterase. 1st Intern. Conf. Antibiotic Res. Impact on Discovery, 1994, Abst. No. P7.
164. O'Hara, K.; Kanda, T.; Ohmiya, K.; Ebisu, T.; Kono, M. Purification and characterization of macrolide 2′-phosphotransferase from a strain of Escherichia coli that is highly resistant to erythromycin. Antimicrob. Agents Chemother. 1989, 33, 1354-1357.
165. Nash, K. A.; Inderlied, C. B. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob. Agents. Chemother. 1995, 39, 2625-2630.
166. Lucier, T. S.; Heitzman, K.; Liu, S.-K.; Hu, P.-C. Transition mutation in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 1995, 39, 2770-2773.
167. Yan, W.; Taylor, D. Characterization of erythromycin resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob. Agents Chemother. 1991, 35, 1989-1996.
168. Clancy, J.; Schmeider, B. J.; Petitpas, J. W.; Manousas, M.; Williams, J. A.; Faiella, J. A.; Girard, A. E.; McGuirk, P. F. Assays to detect and characterize synthetic agents that inhibit the ErmC methyltransferase. J. Antibiot. 1995, 48, 1273-1279.
169. Jevons, M. P. Celbenin-resistant staphylococci. Br. Med. J. 1961, 1, 124-125.
170. Hiramatsu, K. Molecular evolution of MRSA. Microbiol. Immunol. 1995, 39, 531-543.
171. Archer, G. L.; Niemeyer, D. M. Origin and evolution of DNA associated with resistance to methicillin in staphylococci. Trends Microbiol. 1994, 2, 343-346.
172. Hiramatsu, K.; Asada, K.; Suzuki, E.; Okonogi, K.; Yokota, T. Molecular cloning and nucleotide sequence determination of the regulator region of mecA gene in methicillin-resistant Staphylococcus aureus (MRSA) FEBS Lett. 1992, 298, 133-136.
173. Ryffel, C.; Kayser, F. H.; Berger-Bachi, B. Correlation between regulation of mecA transcription and expression of methicillin resistance in staphylococci. Antimicrob. Agents Chemother. 1992, 36, 25-31.
174. Ryffel, C.; Strassle, A.; Kayser, F. H.; Berger-Bachi, B. Mechanisms of heteroresistance in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 1994, 38, 724-728.
175. Hiramatsu, K.; Saito, M.; Suzuki, E. Correlation between PBP2′ production and expression of methicillin resistance in staphylococcal clinical strains. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994, Abstr. No. C63.
176. Maidhof, H.; Reinicke, B.; Bleumel, P.; Berger-Bachi, B.; Labischinski, H. FemA, which encodes a factor essential for expression of methicillin resistance affects glycine content of peptidoglycan in methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains. J. Bacteriol. 1991, 773, 3507-3513.
177. Henze, U.; Sidow, T.; Labischinski, H.; Berger-Bachi, B. Influence of FemB on methicillin resistance and peptidoglycan metabolism in Staphylococcus aureus. J. Bacteriol. 1993, 175, 1612-1620.
178. Hurlimann-Dalel, R. L.; Ryffel, C.; Kayser, F. H.; Berger-Bachi, B. Survey of the methicillin resistance associated genes mecA, mecR1-mecI and femA-FemB in clinical isolates of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 1992, 36, 2617-2621.
179. Gustafson, J.; Strassle, A.; Hachler, H.; Kayser, F. H.; Berger-Bachi, B. The femC locus of Staphylococcus aureus required for methicillin resistance includes the glutamine synthetase operon. J. Bacterial. 1994, 176, 1460-1467.
180. De Lancastre, H.; Tomasz, A. Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 1994, 38, 2590-2598.
181. De Lencastre, H.; De Jonge, B. L. M.; Matthews, P. R.; Tomasz, A. Molecular aspects of methicillin resistance in Staphylococcus aureus. J. Antimicrob. Chemother. 1994, 33, 7-24.
182. Arthur, M.; Molinas, C.; Depardieu, F.; Courvalin, P. Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide precursors in Enterococcus faecium BM4147. J. Bacteriol. 1993, 175, 117-127.
183. Leclerq, R.; Derlot, E.; Duval, J.; Courvalin, P. Plasmid mediated resistance to vancomycinteicoplanin in Enterococcus faecium. N. Engl. J. Med. 1988, 319, 157-161.
184. Arthur, M.; Molinas, C.; Courvalin, P. The VanS-VanR two component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J. Bacterol. 1992, 174, 2582-2591.
185. Bugg, T. D.; Wright, G. D.; Dutka-Malen, S.; Arthur, M.; Courvalin, P.; Walsh, C. T. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 1991, 30, 10408-10415.
186. Dutka-Malen, S.; Molinas, C.; Arthur, M.; Courvalin, P. The VanA glycopeptide resistance protein is related to D-alanyl-D-alanine ligase cell wall biosynthesis enzymes. Mol Gen. Genet. 1990, 224, 364-372.
187. Bugg, T. D.; Dutka-Malen, S.; Arthur, M.; Courvalin, P.; Walsh, C. T. Identification of vancomycin resistance protein VanA as a D-alanine:D-alanine ligase of altered specificity. Biochemistry 1991, 30, 2017-2021.
188. Wu, Z.; Wright, G. D.; Walsh, C. T. Overexpression, purification and characterization of VanX, a D-,D-dipeptidase which is essential for vancomycin resistance in Enterococcus faecium BM4147. Biochemistry 1995, 34, 2455-2463.
189. Billot-Klein, D.; Gutman, L.; Collatz, E.; van Heijenoort, J. Analysis of peptidoglycan precursors in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 1992, 36, 1487-1490.
190. Arthur, M.; Depardieu, F.; Suaith, H. A.; Reynolds, P. E.; Courvalin, P. Contribution of VanY D, D-carboxypeptidase to glycopeptide resistance in Enterococcus faecalis by hydrolysis of peptidoglycan precursors. Antimicrob. Agents Chemother. 1994, 38, 1899-1903.
191. Wright, G. D.; Holman, T. R.; Walsh, C. T. Purification and characterization of VanR and the cytosolic domain of VanS, a two-component regulatory system required for vancomycin resistance in Enterococcus faecium BM4147. Biochemistry 1993, 32, 5057-5063.
192. Holman, T. R.; Wu, Z.; Wanner, B. L.; Walsh, C. T. Identification of the DNA-binding site for the phosphorylated VanR protein required for vancomycin resistance in Enterococcus faecium. Biochemistry 1994, 33, 4625-4631.
193. Meziane-Cherif, D.; Badet-Denisot, M.-A.; Evers, S.; Courvalin, P.; Badet, B. Purification and characterization of the VanB ligase associated with type B vancomycin resistance in Enterococcus faecalis V583. FEBS Lett. 1994, 354, 140-142.
194. Evers, S.; Reynolds, P. E.; Courvalin, P. Sequence of the vanB and ddl genes encoding D-alanine:D-lactate and D-alanine:D-alanine ligases in vancomycin resistant Enterococcus faecalis V583. Gene 1994, 140, 97-102.
195. Evers, S.; Courvalin, P. Regulation of VanB-type vancomycin resistance gene expression by the VanSB-VanRB two-component regulatory system in Enterococcus faecalis V583. Bacteriol. 1996, 178, 1302-1309.
196. Dutka-Malen, S.; Molinas, C.; Arthur, M.; Courvalin, P. Sequence of the vanC gene of Enterococcus gallinarum BM4174 encoding a D-alanine:D-alanine ligase-related protein necessary for vancomycin resistance. Gene 1992, 112, 53-58.
197. Sahm, D. F.; Free, L.; Handwerger, S. Inducible and constitutive expression of vanC-1-encoded resistance to vancomycin in Enterococcus gallinarum. Antimicrob. Agents Chemother. 1995, 39, 1480-1484.
198. Fleischmann, R. D.; Adams, M. D.; White, O.; Clayton, R. A.; Kirkness, E. F.; Kerlavage, A. R.; Bult, C. J.; Tomb, J.-F.; Dougherty, B. A.; Merrick, J. M.; McKenney, K.; Sutton, G.; Fitzhugh, W.; Fields, C.; Gocayne, J. D.; Scott, J.; Shirley, R.; Liu, L.-I.; Glodek, A.; Kelley, J. M.; Weidman, J. F.; Phillips, C. A.; Spriggs, T.; Hedblom, E.; Cotton, M. D.; Utterback, T. R.; Hanna, M. C.; Nguyen, D. T.; Saudek, D. M.; Brandon, R. C.; Fine, L. D.; Fritchman, J. L.; Fuhrmann, J. L.; Geoghagen, N. S. M.; Gnehm, C. L.; McDonald, L. A.; Small, K. V.; Fraser, C. M.; Smith, H. O.; Venter, J. C. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 1995, 269, 496-512.
199. Fraser, C. M.; Gocayne, J. D.; White, O.; Adams, M. D.; Clayton, R. A.; Fleischmann, R. D.; Bult, C. J.; Kerlavage, A. R.; Sutton, G.; Kelley, J. M.; Fritchman, J. L.; Weidman, J. F.; Small, K. V.; Sandusky, M.; Fuhrmann, J. L.; Nguyen, D. T.; Utterback, T. R.; Saudek, D. M.; Phillips, C. A.; Merrick, J. M.; Tomb, J.-F.; Dougherty, B. A.; Bott, K. F.; Hu, P.-C.; Lucier, T. S.; Peterson, S. N.; Smith, H. O.; Hutchison III, C. A.; Venter, J. C. The minimal gene complement of Mycoplasma gentialium. Science 270, 397-403.